COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502

This phase III trial evaluates mammographic breast density in participants with hormone receptor-negative breast cancer enrolled on study A011502. High breast density has been shown to be a strong risk factor for developing breast cancer and decreasing breast density may decrease the risk for breast cancer. Participants treated with aspirin may show reduced breast density on a mammogram.

Research Base: Alliance for Clinical Trials in Oncology
NCT ID: NCT03609021
NCI Protocol Number: A211601
Status: Recruiting

For more information see ClinicalTrials.gov

Interventions

Condition

Breast Carcinoma, Estrogen Receptor Negative, Progesterone Receptor Negative

Trial Type

Other

See a list of participating sites on ClinicalTrials.gov


˄
BACK TO
TOP